secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000950170-25-065603
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports Q1 2025 net loss of $5.6M; INB-100 shows 100% AML relapse-free at 20.1 months
--------------------------------------------------------------------------------

- Net loss $5.6M ($0.07/sh) vs. $8.6M ($0.20/sh) prior year; cash $11.9M as of March 31, 2025.
- Phase 1 INB-100 data: 100% AML patients relapse-free at median 20.1 months follow-up; no CRS/ICANs.
- Presented INB-600 TCE platform at AACR 2025 showing picomolar potency and minimal cytokine release.
- Upcoming oral presentation at ASCO 2025 for INB-200 in glioblastoma (May 30, 2025).
- Raised ~$4.1M net from ATM and warrant exercises in Q1 2025; additional $1.9M gross in April 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017025065603/0000950170-25-065603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017025065603/inab-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-065603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer